Patients with heart failure (HF) suffer from ventilatory abnormalities that are related to poor prognosis.
INTRODUCTION
Despite modern optimal pharmacological management, patients with advanced heart failure (HF) experience severe exercise intolerance mainly manifested by marked dyspnea and fatigue.
HF patients present several respiratory derangements, including restrictive and obstructive breathing pattern 1 decreased lung compliance and hyperventilation. 2 Respiratory muscle weakness 3, 4 and decreased inspiratory capacity 5 have also been observed in these group of patients and are associated with exercise intolerance. Respiratory drive is significantly attenuated, indicating the exertion of a greater respiratory effort and is closely associated with dyspnoea, 6 autonomic nervous system impairment, microcirculation dysfunction, exercise intolerance and disease severity, 7, 8 while it improves after interventions such as exercise training. 9 Long term mechanical support of the advanced failing heart utilizing left ventricular assist devices (LVAD) has become a standard bridge to transplantation and a destination therapy for selected patients with end-stage heart failure. Interestingly severe heart failure can be reversed in selected patients with the combination of LVAD and pharmacologic therapy (bridge to recovery). 10 We hypothesized that LVAD unloading, reversing the chronic stressor state, would induce beneficial effects in terms of myocardial remodeling process and in the increased respiratory drive.
We demonstrated previously a beneficial effect of LVAD implementation on adversely affected parameters of respiratory function, in patients with advanced HF. 11 In the present study we aimed to evaluate the effects of a continuous-flow LVAD on respiratory drive during a 6 month follow-up period after implantation.
MATERIAL AND METHODS

Study population
Our study design was a prospective observational study and the study population consisted of 8 consecutive patients with end-stage HF (6 males and 
Clinical protocol
All patients underwent serial evaluation with cardiopulmonary exercise test (CPET) and respiratory function tests after LVAD implantation.
All patients after LVAD implantation were under optimal medical treatment. In patients with non-ischemic cardiomyopathy, clenbuterol (β2-agonist) was added to standard treatment when maximal regression of the LVEDD had plateaued.
In the study we also included a control group of 8 patients (6 males, 4 with ischemic and 4 with dilated cardiomyopathy, 53±11years, BMI: 28±5kg/m 2 , EF: 28.5±5.8%) with advanced systolic HF, and a peak oxygen uptake ≤ 19ml/kg/min nontreated with LVAD. These patients were randomly chosen from the population followed in our long-term heart failure program. Informed consent was obtained from all patients, and the study was approved by the Human Studies Ethics Committee of our Institution.
Respiratory function tests
After familiarization of the patient with the laboratory environment, measurements of forced vital capacity (FVC) and forced expiratory volume at 1 sec (FEV1) were performed in the sitting position with a closed-circuit spirometer (SensorMedics, Yorba Linda, CA). In all patients the maximal inspiratory pressure (Pimax) was measured at rest, using a system for pulmonary tests as previously described. 4 All tests were performed 1, 3 and 6 months after LVAD implantation.
Measurements of the mouth occlusion pressure (P0.1) were made 100ms after the onset of inspiration at rest. P0.1 is the http://epublishing.ekt.gr | e-Publisher: EKT | Downloaded at 12/10/2019 08:43:20 | Then the valve was randomly closed, to minimize the likelihood of a deliberate respiratory effort exerted by the patient against the valve. The measurement was repeated 6-8 times, and P0.1 was calculated as the average of 4 measurements that differed by <5%. 9 P0.1 was expressed as an absolute value (cmH2O), and as a percentage of Pimax (P0.1/ Pimax) to normalize its measurement for individual differences in inspiratory muscle strength.
Exercise test
Each subject performed a symptom-limited ramp-incremental exercise test, so as to aim for a test of 8-12 min duration (work increments calculated as previously described 9 ). The subjects 
RESULTS
All LVAD patients had impaired respiratory drive at initial evaluation which presented a trend towards normalization during the 6 month follow-up period. Specifically a decrease in P0.1 and P0.1/Pimax% (Figure 1) as well as an increase in Pimax and VT at peak exercise was observed ( Table 1 ). The patients in the control group had a statistically insignificant trend for a decrease in P0.1.
A significant increase in exercise capacity was noted in all LVAD patients, expressed by VO2p and VO2AT, as previously described. 11 The Pimax increase after 6 months of follow-up was inversely correlated with the VO2p increase (r=-0.88; p<0.05).
No deference in exercise capacity was observed in the control group.
A significant decrease in LVEDD, LVESD and an improvement in LVEF is observed at 1, 3 and 6 months after LVAD implantation (Table 2) .
DISCUSSION
The main findings of the study were that implantation of a con- Autonomous nervous system is severely deranged immediately after LVAD implantation and these abnormalities persist 3 months after LVAD implantation with a tendency to improve. 14 The autonomic derangement being restored after LVAD implantation through unloading of the failing heart, may contribute to respiratory drive restoration up to a point 15, 16 improving the adrenergic pathways and the sympathetic innervation.
Previous studies have shown a significant reverse remodeling of the failing myocardium, as well as, a hemodynamic improvement after LVAD implantation. [17] [18] [19] Our study results are consistent with those of previous studies in patients with nonischemic HF.
Interestingly, in our study a significant inverse correlation of the percentage changes of Pimax and VO2p was evident after six months of LVAD support mainly evidenced in non-ischemic LVAD patients. An explanation of these findings may be the additional effect of clenbuterol in these patients comparing to ischemic LVAD patients and its greater effect on the peripheral muscles strength, with 'less positive' effects to muscle oxidative capacity.
Limitations
The small number of patients and the short follow up period are the main limitations of our study. We also included patients with ischemic and non-ischemic HF patients, although the sample size was small for separate analysis according to HF etiology. Finally the use of clenbuterol might interpret alongside with LVAD implantation.
CONCLUSIONS
Concluding, with this study we demonstrate that a continuousflow LVAD induces a progressive and significant improvement of respiratory drive and Left ventricle reverse remodeling during a 6 month follow-up period.
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